<DOC>
	<DOCNO>NCT00732875</DOCNO>
	<brief_summary>This trial extension part P04280 ( placebo-controlled , double-blind , randomize study chronic treatment infliximab approximately 140 patient , NCT00202852 ) . This study conduct 6 study center South Korea . After completion last follow-up visit Week 30 code break main double-blind trial , subject randomize placebo group treat infliximab-containing regimen maintain clinical response time study completion provide open-label infliximab treatment condition additional safety data collect .</brief_summary>
	<brief_title>A Trial Anti-TNF Chimeric Monoclonal Antibody ( cA2 ) Korean Patients With Active Rheumatoid Arthritis Despite Methorexate ( Extension Part ) ( Study P05645 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients receive placebo main doubleblind study ( P04280 , NCT00202852 ) Patients receive Infliximabcontaining regimen show clinical response week 30 main doubleblind study ( P04280 ) [ Main doubleblind study ( P04280 , NCT00202852 ) inclusion criterion ] Diagnosis rheumatoid arthritis ( RA ) accord revise 1987 criterion American Rheumatism Association ( Arnett et al , 1988 ) . The disease diagnose &gt; 6 month prior screen . Active disease time screen preinfusion define : &gt; =6 swollen joint &gt; =6 tender joint 2 follow : morning stiffness &gt; =45 min erythrocyte sedimentation rate ( ESR ) &gt; =28 mm/h Creactive protein ( CRP ) &gt; =20 mg/L Men woman , &gt; =18 &lt; =75 year age Men woman childbearing potential must use adequate birth control measure ( abstinence , oral contraceptive , intrauterine device ( IUD ) , barrier method spermicide , surgical sterilization ) continue precaution 6 month receive last infusion . Must use oral parenteral MTX &gt; 3 month break ( ) treatment &gt; 2 week total period . Patients must stable dose &gt; =12.5 mg/wk ( maximum 20 mg/wk ) &gt; 4 week prior screen . Must stable dose folic acid prophylaxis &gt; 4 week prior screen . Patients use oral corticosteroid , must stable dose &lt; =10 mg/day &gt; 4 week prior screen . If currently use corticosteroid patient must receive corticosteroid &gt; 4 week prior screen . If use nonsteroidal antiinflammatory drug ( NSAIDs ) , patient stable dose &gt; 4 week prior screen . The screening laboratory test must meet following criterion : Hemoglobin &gt; =5.3 mmol/L ( &gt; =8.5 g/dL ) , provide low hemoglobin level due nutritional deficiency due disease chronic RA white blood cell ( WBC ) &gt; =3.5 x 10^9/L ( &gt; =3.5 x 10^3/mm^3 ) Neutrophils &gt; =1.5 x 10^9/L ( &gt; =1.5 x 103/mm^3 ) Platelets &gt; =100 x 10^9/L ( &gt; =100 x 103/mm^3 ) Serum transaminase &lt; =2 time upper limit normal Alkaline phosphatase level &lt; =2 time upper limit normal Serum creatinine &lt; =150 Âµmol/L ( &lt; =1.7 mg/dL ) Must able adhere study visit schedule protocol requirement . Must capable give informed consent consent must obtain prior study procedure include washout period . Exclusion criterion main doubleblind study ( P04280 , NCT00202852 ) [ Main doubleblind study ( P04280 , NCT00202852 ) exclusion criterion ] Pregnant woman , nurse mother , plan pregnancy within 1.5 year enrollment . Patients incapacitated , largely wholly bedridden confine wheelchair , little ability selfcare . Patients current systemic inflammatory condition sign symptom might confound evaluation benefit infliximab , eg Lyme disease , rheumatic disease RA . Use disease modify antirheumatic drug ( DMARDs ) MTX within 4 week prior screen . ( If patient prior exposure leflunomide within past 6 month , cholestyramine 8 g give 3 time daily 11 day rapidly low plasma level leflunomide . ) Use intraarticular , i.m . i.v . corticosteroid ( include i.m . ACTH ) within 4 week prior screen . Have previously treat infliximab genetic recombinant therapy RA ( e.g . etanercept , adalimumab ) Treatment therapeutic agent target reduce TNF ( eg , pentoxifylline thalidomide ) within previous 3 month . Treatment investigational drug within previous 3 month . Prior use cyclophosphamide , nitrogen mustard , chlorambucil , alkylating agent . History clinically significant adverse reaction murine chimeric protein , include limited allergic reaction . History infect joint prosthesis within previous 5 year . Serious infection , hepatitis , pneumonia , pyelonephritis previous 3 month . Chronic infectious disease chronic renal infection , chronic chest infection bronchiectasis sinusitis . Active tuberculosis ( TB ) . Also exclude patient evidence latent TB ( positive purify protein derivative [ PPD ] skin test history latent TB ) without adequate therapy TB initiate prior first infusion study drug . Also exclude patient evidence old latent TB infection without documented adequate therapy , treat antitubercular therapy trial . Patients current close contact individual active TB also exclude . Additionally , patient complete treatment active TB within previous 2 year explicitly exclude trial . Patients household member history active pulmonary TB thorough evaluation TB prior study enrollment recommend local infectious disease specialist publish local guideline TB control agency . Also exclude patient opportunistic infection , include limited evidence active cytomegalovirus , active Pneumocystis carinii , aspergillosis , atypical mycobacterial infection , etc , within previous 6 month . Current sign symptom severe , progressive uncontrolled renal , hepatic , hematologic , gastrointestinal , endocrine , pulmonary , cardiac , neurologic cerebral disease . History lymphoproliferative disease include lymphoma sign suggestive possible lymphoproliferative disease , lymphadenopathy unusual size location ( nodes posterior triangle neck , infraclavicular , epitrochlear , periaortic area ) , splenomegaly . Any current know malignancy history malignancy within previous 5 year , except squamous basal cell carcinoma skin treat evidence recurrence . Patients moderate severe heart failure ( New York Heart Association [ NYHA ] class III/IV ) . Patients preexist recent onset central nervous system demyelinate disorder . Known recent substance abuse ( drug alcohol ) . Patients multiple venipuncture feasible due poor tolerability lack easy access . Have know infection HIV know active hepatitis B/C infection ( include associate chronic active hepatitis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>